The Ipamorelin and CJC-1295 stack is one of the most widely studied peptide combinations in growth hormone secretagogue research. When combined, these two peptides may produce a synergistic effect on pulsatile growth hormone (GH) release — with CJC-1295 extending the duration of GH elevation and Ipamorelin providing targeted, ghrelin-mimetic stimulation with a comparatively mild side-effect profile. This guide consolidates the available research literature, commonly referenced protocols, and practical considerations for investigators working with this peptide combination.
Among the growing catalog of synthetic peptides studied for their influence on the growth hormone axis, the Ipamorelin and CJC-1295 stack has attracted significant attention from both clinical researchers and the broader peptide research community. These two compounds operate through complementary mechanisms — one acting as a growth hormone-releasing hormone (GHRH) analog and the other as a selective growth hormone secretagogue receptor (GHS-R) agonist. Understanding how they interact at a mechanistic level is essential for anyone designing or evaluating research protocols involving this combination.
This research guide covers the pharmacology of each peptide individually, the rationale behind combining them, dosing frameworks reported in the literature, reconstitution and handling considerations, and a summary of reported observations from published studies and anecdotal research logs.
What Is CJC-1295? Pharmacology and Mechanism of Action
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), originally developed by ConjuChem Biotechnologies. It consists of a modified 29-amino-acid GHRH peptide. The most commonly referenced form in research contexts is CJC-1295 without DAC (Drug Affinity Complex), sometimes referred to as Modified GRF (1-29). This version has a shorter half-life compared to the DAC-conjugated variant, which binds to albumin and extends its circulation time to several days.
CJC-1295 without DAC functions by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone. Importantly, this stimulation preserves the body’s natural pulsatile pattern of GH release, rather than producing a continuous, non-physiological elevation. Four amino acid substitutions at positions 2, 8, 15, and 27 protect the peptide from enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), improving its bioavailability relative to endogenous GHRH.
Published pharmacokinetic data suggest that CJC-1295 without DAC has a half-life of approximately 30 minutes, with peak GH levels observed roughly 30–60 minutes after subcutaneous administration. The DAC-conjugated version extends the half-life to approximately 6–8 days, but it tends to produce a more sustained (and less pulsatile) GH elevation, which is why many research protocols favor the non-DAC form when stacking with Ipamorelin.
What Is Ipamorelin? Pharmacology and Mechanism of Action
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Developed by Novo Nordisk in the late 1990s, it was identified as one of the most selective GHS-R agonists available, meaning it stimulates GH release without significantly elevating cortisol, prolactin, or aldosterone at standard research doses — a notable distinction from earlier secretagogues like GHRP-6 and GHRP-2.
Ipamorelin stimulates GH release through a mechanism distinct from GHRH. By activating GHS-R1a receptors, it amplifies the GH pulse initiated by GHRH signaling while also partially suppressing somatostatin tone (the hormone that inhibits GH release). Its selectivity profile makes it particularly attractive in research settings where isolating GH-axis effects from broader hormonal disruption is desirable.
The half-life of Ipamorelin is approximately two hours, with peak GH concentrations typically observed within 40 minutes of subcutaneous injection. Studies in both animal models and human subjects have demonstrated dose-dependent GH release with a clear ceiling effect, meaning that increasing the dose beyond a certain threshold does not proportionally increase GH output.
Rationale for Combining Ipamorelin and CJC-1295
The scientific rationale for stacking Ipamorelin with CJC-1295 without DAC rests on the principle of synergistic amplification through dual-pathway activation. CJC-1295 initiates the GH pulse by stimulating the GHRH receptor, while Ipamorelin amplifies that pulse through the GHS-R1a pathway and helps reduce somatostatin’s inhibitory influence. The result, as suggested by comparative GH-response studies, is a GH release profile that is greater in amplitude than either peptide administered alone.
This concept is analogous to a well-documented phenomenon in endocrinology: the co-administration of GHRH and GHRP compounds produces a GH response that is not merely additive but synergistic. A landmark study by Bowers et al. demonstrated that combining GHRH with a GHS-R agonist could amplify peak GH levels by a factor of approximately 2–3 compared to either agent alone. While Ipamorelin and CJC-1295 are more refined analogs, the same mechanistic principle applies.
Additionally, combining these peptides preserves the pulsatile nature of GH secretion — a feature considered physiologically important because continuous GH elevation can lead to receptor desensitization and may not replicate the downstream signaling patterns (including IGF-1 production in the liver) as effectively as pulsed release.
Commonly Referenced Dosing Protocols in Research
The following table summarizes the dosing parameters most frequently cited in published research, peptide vendor guidelines, and community-sourced research logs. These figures are presented for informational context only and do not constitute dosing recommendations.
| Parameter | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Typical Research Dose | 100–300 mcg per administration | 100–300 mcg per administration |
| Frequency | 1–3 times daily | 1–3 times daily |
| Administration Route | Subcutaneous injection | Subcutaneous injection |
| Preferred Timing | Morning, post-workout, and/or before bed | Morning, post-workout, and/or before bed |
| Approximate Half-Life | ~30 minutes | ~2 hours |
| Common Protocol Duration | 8–12 weeks | 8–12 weeks |
| Fasting Recommendation | Administer on an empty stomach (no food 1–2 hours prior) | Administer on an empty stomach (no food 1–2 hours prior) |
The before-bed dosing window is frequently emphasized in research protocols because it coincides with the natural nocturnal GH pulse, potentially amplifying endogenous secretion patterns. Food intake — particularly carbohydrates and fats — can blunt the GH response by elevating insulin and free fatty acids, which is why fasted administration is commonly advised in study designs.
Reconstitution, Storage, and Handling Guidelines
Both Ipamorelin and CJC-1295 without DAC are supplied as lyophilized (freeze-dried) powders and must be reconstituted before use. Proper handling is critical to maintaining peptide integrity and ensuring consistent dosing across a research protocol.
| Handling Step | Guideline |
|---|---|
| Reconstitution Solvent | Bacteriostatic water (BAC water, 0.9% benzyl alcohol) |
| Reconstitution Volume | Typically 1–2 mL per vial (varies by vial size; adjust calculations accordingly) |
| Reconstitution Technique | Inject BAC water slowly along the vial wall; allow the peptide to dissolve without shaking or agitating |
| Storage (Unreconstituted) | Refrigerated (2–8°C) or frozen (−20°C) for long-term storage |
| Storage (Reconstituted) | Refrigerated (2–8°C); use within 21–28 days |
| Light Sensitivity | Keep vials away from direct light; store in a dark environment |
| Needle Gauge | 29–31 gauge insulin syringes are standard for subcutaneous administration |
Researchers should note that peptide purity, sourcing, and third-party testing verification (e.g., HPLC and mass spectrometry certificates of analysis) are critical variables that can significantly affect the reproducibility and validity of any experimental outcomes.
Track your peptide protocol
Log every dose, cost, and observation in one organized spreadsheet.
Reported Observations in the Research Literature
The body of literature directly evaluating the combined administration of Ipamorelin and CJC-1295 without DAC in controlled human trials remains limited. However, individual studies on each peptide, combined with the broader GHRH/GHRP synergy research, provide a substantive foundation for understanding expected outcomes.
Growth Hormone Elevation: Studies on CJC-1295 (with DAC) demonstrated sustained GH and IGF-1 elevation for up to 6 days following a single dose in healthy adults (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism). While these findings apply to the DAC variant, they confirm the compound’s ability to robustly stimulate the GH axis. Ipamorelin studies in human subjects have demonstrated dose-dependent GH release with minimal impact on cortisol, ACTH, prolactin, and aldosterone (Raun et al., 1998, European Journal of Endocrinology).
Selectivity and Side-Effect Profile: A distinguishing characteristic of this particular stack is the relative selectivity of both peptides. Unlike GHRP-6, which notably stimulates appetite through ghrelin-pathway activation, Ipamorelin produces significantly less appetite stimulation. CJC-1295 without DAC, acting specifically through the GHRH receptor, does not engage ghrelin pathways at all. This combined selectivity profile is a primary reason the stack is favored in research over alternatives like GHRP-6 + CJC-1295 or hexarelin combinations.
Commonly Reported Anecdotal Observations: Across research community forums and protocol logs, the most frequently cited observations include improved sleep quality (particularly deeper slow-wave sleep), gradual changes in body composition over 8–12 week protocols, and mild transient side effects such as injection-site redness, water retention, and tingling or numbness in the extremities. These anecdotal reports have not been systematically validated in large-scale clinical trials and should be interpreted with appropriate caution.
Potential Limitations and Areas Requiring Further Study
Despite the mechanistic plausibility and preliminary supportive data, several important limitations must be acknowledged in any discussion of the Ipamorelin and CJC-1295 stack:
Lack of Large-Scale Combined Trials: No large, randomized, placebo-controlled trials have evaluated the specific combination of Ipamorelin and CJC-1295 without DAC administered concurrently in human subjects. Most evidence is extrapolated from single-agent studies and GHRH/GHRP class-level synergy research.
Long-Term Safety Data: Extended-use safety profiles for this combination are not well-established. While short-term administration of each peptide individually appears to be well-tolerated in published studies, the consequences of prolonged co-administration over months or years remain largely uncharacterized.
Individual Variability: GH responses to secretagogues vary considerably between individuals based on age, body composition, baseline IGF-1 levels, sleep quality, and other physiological variables. Protocols that produce robust GH elevations in one subject may yield more modest results in another.
Regulatory Status: Neither Ipamorelin nor CJC-1295 is approved by the FDA for therapeutic use. They are classified as research chemicals in most jurisdictions. Researchers must ensure compliance with all applicable local regulations governing the procurement, handling, and use of synthetic peptides.
Summary and Conclusion
The Ipamorelin and CJC-1295 without DAC stack represents one of the most pharmacologically rational peptide combinations for investigating pulsatile growth hormone release. By engaging two distinct receptor pathways — GHRH-R and GHS-R1a — this combination leverages a well-documented synergy mechanism while maintaining a comparatively selective hormonal profile. The existing preclinical and early clinical data on each peptide individually are encouraging, but the field would benefit substantially from dedicated combination studies with rigorous design and adequate sample sizes.
For researchers considering this stack, careful attention to peptide sourcing quality, reconstitution procedures, dosing consistency, protocol duration, and systematic data collection will be essential for generating meaningful and reproducible observations. As the peptide science landscape continues to evolve, this combination will likely remain a focal point of GH-axis investigation.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.